Berdazimer 10.3% gel (Zelsuvmi – Ligand), a first-in-class nitric oxide-releasing agent, has been approved by the FDA for topical treatment of molluscum contagiosum in patients ≥1 year old. It is the second drug to become available in the US for treatment of molluscum contagiosum and the first that can be applied by the patient or caregiver at home; cantharidin 0.7% solution (Ycanth), which is applied by a healthcare professional, was approved earlier for use in patients ≥2 years old.1
MOLLUSCUM CONTAGIOSUM ― A skin infection caused by...
- Upadacitinib (Rinvoq) for Giant Cell Arteritis
- Teal Wand — An At-Home Cervical Cancer Screening Device
- Onapgo — An Apomorphine Subcutaneous Infusion for Parkinson's Disease
- In Brief: Low-Dose Chlorthalidone (HemiClor) for Hypertension
- COVID-19 Update: Full Approval for Novavax COVID-19 Vaccine
- COVID-19 Update: mRNA COVID-19 Vaccines and Myocarditis
- COVID-19 Update: mNEXSPIKE — A New Moderna mRNA Vaccine for COVID-19
- Addendum: Drugs for Chronic Heart Failure
- Avmapki Fakzynja Co-Pack for Ovarian Cancer (online only)
- Penpulimab (Anniko) for Nasopharyngeal Carcinoma (online only)
- Prademagene Zamikeracel (Zevaskyn) for Recessive Dystrophic Epidermolysis Bullosa (online only)
- Retifanlimab (Zynyz) for Anal Cancer (online only)
ISSUE
The oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq – Abbvie) has been approved by the FDA for treatment of giant cell arteritis. Upadacitinib was approved earlier for treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, nonradiographic axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease.1-4
THE DISORDER — Giant cell arteritis is a systemic large-vessel vasculitis that usually occurs in adults ≥50 years old. It can cause headache, jaw claudication, flu-like symptoms, vision loss, and rarely aortic aneurysm or dissection. High-dose corticosteroid therapy has been effective in inducing remission, but treatment must be continued for months or years, adverse effects can be severe, and relapses are common.5 Use of the interleukin-6 (IL-6) receptor antagonist tocilizumab (Actemra, and biosimilars) has been …